about
cDNA micro array identification of a gene differentially expressed in adenovirus type 5- versus type 12-transformed cellsDifferential expression of tapasin and immunoproteasome subunits in adenovirus type 5- versus type 12-transformed cellsMulticenter Analytical Validation of Aβ40 Immunoassays.Methods for analysis of amyloid-β aggregates.A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an exampleCyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptorMicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid.Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP.Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid.The diagnostic value of CSF amyloid-β(43) in differentiation of dementia syndromes.Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls.Dickkopf-related protein 3 is a potential Aβ-associated protein in Alzheimer's Disease.Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged.MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol.Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.Inhibition of α-synuclein aggregation by small heat shock proteins.Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells.Serum NFL discriminates Parkinson disease from atypical parkinsonismsCerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from ControlsTDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathiesDetection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson diseaseDiagnosis of progressive supranuclear palsy: can measurement of tau forms help?CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSDApolipoprotein D: a potential biomarker for cerebral amyloid angiopathy
P50
Q28142258-9A158626-FCB8-441F-A8DB-949F48CA0675Q28570543-221AE8A2-D1BE-4E32-BBBB-559EE2EDC6C2Q33871427-64AA5490-3FC8-41A8-A1CA-CE1E5FE453E9Q34095967-D8095E63-A2AE-4C4C-B37B-42BFA525BF37Q36323907-16908899-177D-4722-8CBF-CFED7444D5B3Q36324985-13155CBC-B65C-4150-8413-64432CF76E1FQ36994237-2A5D4BFE-CB9D-4D13-8681-D296CE057693Q37789575-DEEC92E3-1ABF-4186-8A20-DA647D07B54AQ38741714-C508E969-8A5C-4C34-84EC-A2D3557A66A3Q38877405-07A181AE-B7F5-4EF1-8DF4-332246517804Q40267156-CC6879B0-02E9-4D90-92DF-90F803F07C6DQ42818558-50650417-E8FC-42A6-B825-6CC9801399FAQ43517732-FD871DC2-CC30-45C7-B761-FBD6685A0785Q44001848-9A1C0090-FAE1-470B-91D5-55C6C594A685Q46430845-9E9C7F2D-9FD0-4E3D-B9C6-9D9EAC60B283Q47982531-B256F8B6-99DD-4BFD-B56C-AA025AED6656Q48031109-4CD95AC9-12FA-4727-A08B-47DE58E2AB4DQ48105192-AD1CA602-613E-4366-B7D5-F40FA10EF7BAQ48261152-182BC23A-B2ED-40D4-9047-171C44D636FEQ48380481-CACC05E9-A339-4DA2-AB39-E0FEBAEAB42DQ48430049-1AA8DBE5-4E13-4E6E-8A32-E0E6989D83D6Q48497503-0D14CD31-A816-4860-AEC5-D298FF441410Q48542914-04097058-4000-4DA7-889C-BC3247B5897EQ51763094-A42FC0DE-6488-4917-BE7E-978EB54EBF43Q53322022-D6C98EB8-69D6-4E80-83F3-FA48644D06D7Q53402600-0BCFBC1C-74E0-438B-AED1-EC6A63597E68Q64778335-BB2763DA-AFE9-420B-B273-A07B3BD90CDFQ64814784-F3AB1E67-8A49-4A27-971F-50940D9741D4Q82288832-D614C930-640B-4874-AB0F-835721D6D106Q84654628-A68D204C-619B-43C1-9D0C-AF95B955A5FAQ85195793-45E5ABF9-E945-48C4-B624-5522ACB828A5Q90690391-E30835E5-4133-4E9A-AA8A-62F6E1733F35Q92225513-F99067F6-1BDA-4B39-B4E6-EB7795A68E4E
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
H B Kuiperij
@en
H B Kuiperij
@nl
type
label
H B Kuiperij
@en
H B Kuiperij
@nl
prefLabel
H B Kuiperij
@en
H B Kuiperij
@nl
P106
P31
P496
0000-0002-0635-7428